Related Experiment Videos
[Indications for curietherapy of the prostate using permanent implants]
L Chauveinc1, T Flam, S Solignac
1Département de radiothérapie, institut Curie, 26, rue d'Ulm, 75005 Paris, France. laurent.chauveinc@curie.net
Summary
Brachytherapy offers excellent long-term biochemical control for localized prostate cancer, comparable to surgery and radiotherapy but with fewer complications. Patient selection is crucial for optimal outcomes.
Area of Science:
- Oncology
- Urology
Context:
- Brachytherapy has gained prominence for treating localized prostate cancer over the past decade.
- Recent long-term data (10-12 years) show biochemical control rates comparable to surgery and conformal radiotherapy.
Purpose:
- To evaluate brachytherapy as an effective treatment option for localized prostate cancer.
- To compare its efficacy and complication rates with established treatments like surgery and external beam radiotherapy.
Summary:
- Brachytherapy demonstrates comparable 10-12 year biochemical control rates to surgery and radiotherapy for localized prostate cancer.
- It offers a low complication rate when applied to carefully selected patients (T1/T2, PSA < 10 ng/mL, Gleason score < 7).
- Factors like prostate volume, hip mobility, and prior urinary surgery influence technical feasibility and patient selection.
Impact:
- Brachytherapy provides a viable alternative to radical prostatectomy and external beam radiotherapy for select patients.
- It achieves satisfactory long-term oncological outcomes with a favorable safety profile.